Cardiogenic shock in cancer

Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary emboli...

Full description

Saved in:
Bibliographic Details
Published in:Heart failure reviews 2019-11, Vol.24 (6), p.997-1004
Main Authors: Keramida, Kalliopi, Parissis, John T., Chioncel, Ovidiu, Farmakis, Dimitrios
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - complications
Antineoplastic Agents - adverse effects
Cancer
Cardiac Tamponade - complications
Cardiology
Cardiomyopathies - complications
Cardiomyopathy
Chemotherapy
Embolism
Heart diseases
Humans
Medical prognosis
Medicine
Medicine & Public Health
Myocarditis
Myocarditis - complications
Neoplasms - complications
Neoplasms - mortality
Neoplasms - therapy
Pulmonary Embolism - complications
Radiation therapy
Radiotherapy - adverse effects
Secondary Prevention - methods
Shock, Cardiogenic - chemically induced
Shock, Cardiogenic - diagnosis
Shock, Cardiogenic - etiology
Shock, Cardiogenic - therapy
Surgery
Takotsubo Cardiomyopathy - complications
Tamponade
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary embolism, tamponade, and cardiac herniation. In these conditions, CS may be related to cancer itself or to cancer therapy, including surgery, chemotherapy, or radiotherapy. Given the significantly improved overall survival of patients with malignancies, the early recognition and proper management of CS in cancer become increasingly important. In the present paper, we review the available evidence on CS in patients with malignancies and highlight issues related to its management.
ISSN:1382-4147
1573-7322
DOI:10.1007/s10741-019-09819-9